Ro, the leading direct-to-patient healthcare company, announced today that it is working with Novo Nordisk on the nationwide launch of the new Wegovy® pill. Patients today can come to Ro.co for the easiest way to access the first and only oral GLP-1 weight loss medication at the lowest available cash pay price. Ro first integrated directly with Novo Nordisk in April 2025 and has been a key part of the manufacturer’s direct-to-patient expansion to date.
“The Wegovy pill is the most recent example of Novo Nordisk’s decades-long commitment to obesity treatment. Now more than ever, it is critically important to meet the millions of people who have not previously chosen obesity medications due to administration preferences where they are,” said Dave Moore, Executive Vice President, U.S. Operations for Novo Nordisk. “By tapping into Ro’s vertically integrated platform, clinically eligible patients are able to seamlessly access the Wegovy® pill from diagnosis to payment to delivery, all in one place — at our lowest prices.”